Dosing and administration
Only IMAAVY is administered via an IV infusion every 2 weeks*—a dosing schedule unique among FDA-approved FcRn blockers for gMG1
Initial dosing
30 mg/kg IV infusion administered
over at least 30 minutes1
Maintenance dosing
15 mg/kg IV infusion administered
over at least 15 minutes1†
Dosing frequency
Continue the maintenance dosage every 2 weeks thereafter1‡
Monitor the patient for 30 minutes after each infusion for signs or symptoms of an infusion-related or hypersensitivity reaction. If an adverse reaction occurs during administration of IMAAVY, the infusion may be slowed or stopped.1
In the Phase 3 pivotal trial and its extension study, 11% (n=20/186) of patients taking IMAAVY experienced infusion-related reactions, which occurred within 1 hour to 2 days of administration.1
Infusion-related reactions were mild to moderate in severity; no patients experienced an infusion-related reaction that required discontinuation of IMAAVY.1
*After an initial dosage of 30 mg/kg administered once via IV infusion over at least 30 minutes.1
†Two weeks after the initial dosage.1
‡If a scheduled infusion appointment is missed, the maintenance dosage of IMAAVY should be administered as soon as possible. Resume dosing every 2 weeks thereafter.1
IMAAVY may be given in a variety of settings
IMAAVY can help you and your patients plan in advance with in-office or at-home infusion options.
At patient's home
An infusion service provider may be able to coordinate at-home administration of IMAAVY.
At your office
You can prescribe and administer IMAAVY in your office.
At a hospital
You can send patients to hospitals where they can receive IMAAVY as an outpatient service (not requiring hospital admission).
FcRn=neonatal fragment crystallizable receptor; IV=intravenous.
Once you’ve made the decision to prescribe IMAAVY
Find out more information about IMAAVY dosing and administration
